Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755846 | 0.78 | PEPD (0.57) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL5521712 | 0.78 | IDO1 (0.67) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL5146332 | 0.77 | ALDH1A1 (0.60) | IDO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3069525 | 0.77 | ALDH1A1 (0.57) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL6390723 | 0.74 | CA1 (0.54) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL27644436 | 0.72 | ALDH1A1 (0.58) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL3074944 | 0.72 | ALDH1A1 (0.70) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL836968 | 0.72 | ALDH1A1 (0.62) | IDO1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL5170073 | 0.72 | KMT2A (0.51) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17913053 | 0.72 | IDO1 (1.00) | IDO1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7022702-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | DERMIRA (CANADA), INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND1, CCND3 | IDO1 241/4885MAPT 4864/4885RAB9A 4479/4885 |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND3, ACIN1 | IDO1 897/4885MAPT 4790/4885RAB9A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.